Detalhe da pesquisa
1.
A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling.
Mol Cell Proteomics
; 20: 100067, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33775892
2.
Homologous Recombination Deficiency: Concepts, Definitions, and Assays.
Oncologist
; 27(3): 167-174, 2022 03 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35274707
3.
Limited antitumor activity of combined BET and MEK inhibition in neuroblastoma.
Pediatr Blood Cancer
; 67(6): e28267, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32307821
4.
SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.
Nature
; 510(7504): 283-7, 2014 Jun 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24847881
5.
A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Nat Chem Biol
; 11(6): 432-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25915199
6.
Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
Blood
; 123(5): 697-705, 2014 Jan 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-24335499
7.
A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor-positive/HER2-negative Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 30(2): 334-343, 2024 01 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992310
8.
A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
Clin Cancer Res
; 29(4): 711-722, 2023 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36350312
9.
Inhibiting Type I Arginine Methyltransferase Activity Promotes T Cell-Mediated Antitumor Immune Responses.
Cancer Immunol Res
; 10(4): 420-436, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35181787
10.
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Nat Commun
; 13(1): 5676, 2022 09 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36167829
11.
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.
JNCI Cancer Spectr
; 4(2): pkz093, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32328561
12.
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer.
Nat Med
; 25(3): 403-418, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30842676
13.
Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss.
Cancer Cell
; 36(1): 100-114.e25, 2019 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31257072
14.
Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia.
Nat Commun
; 10(1): 2723, 2019 06 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222014
15.
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation.
Cancer Cell
; 36(2): 194-209.e9, 2019 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31408619
16.
"Z4" Complex Member Fusions in NUT Carcinoma: Implications for a Novel Oncogenic Mechanism.
Mol Cancer Res
; 16(12): 1826-1833, 2018 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30139738
17.
MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.
Oncogenesis
; 7(4): 35, 2018 Apr 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674704
18.
Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.
Sci Rep
; 8(1): 9711, 2018 06 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-29946150
19.
Targeting Histone Methylation in Cancer.
Cancer J
; 23(5): 292-301, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28926430
20.
PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.
Cell Rep
; 21(12): 3498-3513, 2017 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29262329